CorMedix Inc.
CorMedix Inc. is listed today as CorMedix Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2009 | $3 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company CorMedix Inc., its revenue in fiscal 2025 came from these product and service lines: DefenCath $258.81 million (83%), Melinta Portfolio $45.53 million (15%), Contract revenue $7.36 million (2%).
Annual report (SEC XBRL) · Dec 2025
CorMedix Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2009).
SEC Form D · Nov 2009
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2009
Products and services#
No products or services of CorMedix Inc. are on record.
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Cora M. Tellez | Person | not stated | not stated | Held Series C-3 preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Gary A. Gelbfish | Person | not stated | not stated | Held Series C-3 preferred stock, director (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.
Largest shareholders today
Institutions holding CorMedix Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$50 M8.11%
- Deep Track Capital, LP$48 M7.89%
- Vanguard Capital Management LLC$23 M3.84%
- American Century Companies Inc$21 M3.42%
- State Street Corp$20 M3.32%
- UBS Group AG$17 M2.83%
- Geode Capital Management, LLC$15 M2.40%
- Royce & Associates LP$13 M2.09%
- Oberweis Asset Management Inc/$10 M1.66%
- Goldman Sachs Group Inc$10 M1.57%
- Marshall Wace, LLP$9 M1.50%
- Alyeska Investment Group, L.P.$7 M1.07%
- Armistice Capital, LLC$6 M1.05%
- Vanguard Portfolio Management LLC$6 M0.92%
- Trexquant Investment LP$6 M0.90%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| John Houghton | Executive officer | Nov 2009 |
| Mark Houser | Executive officer | Nov 2009 |
| Stephen Pilatzke | Executive officer | Nov 2009 |
| Antony Pfaffle | Director | Nov 2009 |
| Bruce Cooper | Director | Nov 2009 |
| John Houghton | Director | Nov 2009 |
| Mahendra Patel | Director | Nov 2009 |
| Russell Ellison | Director | Nov 2009 |
| Timothy Hofer | Director | Nov 2009 |
| Lindsay Rosenwald | Dr. Rosenwald and trusts established for the benefit of his family own approximately 17.6% of our common stock, and Para | Nov 2009 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.